1,013
Views
3
CrossRef citations to date
0
Altmetric
Editorials: Cell Cycle Features

Killing AML: RIPK3 leads the way

, &
Pages 3-4 | Received 22 Aug 2016, Accepted 28 Aug 2016, Published online: 20 Oct 2016

References

  • Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506:328-33; PMID:24522528; http://dx.doi.org/10.1038/nature13038
  • Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, DeAngelo DJ, Frattini MG, Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151:344-55; PMID:23063124; http://dx.doi.org/10.1016/j.cell.2012.08.038
  • Yabal M, Müller N, Adler H, Knies N, Groß CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwälder M, Strasser A, et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell reports 2014; 7:1796-808; PMID:24882010; http://dx.doi.org/10.1016/j.celrep.2014.05.008
  • Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer cell 2016; 30:75-91; PMID:27411587; http://dx.doi.org/10.1016/j.ccell.2016.06.002
  • Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, Lich JD, Finger J, Kasparcova V, Votta B, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Molecular cell 2014; 56:481-95; PMID:25459880; http://dx.doi.org/10.1016/j.molcel.2014.10.021
  • Brumatti G, Ma C, Lalaoui N, Nguyen N-Y, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Science translational medicine 2016; 8:339ra69; http://dx.doi.org/10.1126/scitranslmed.aad3099
  • Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen N-YN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, et al. Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mimetics. Cancer cell 2016; 29:145-58; PMID:26859455; http://dx.doi.org/10.1016/j.ccell.2016.01.006

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.